A Director at Onconova Therapeutics (ONTX) is Buying Shares


Today, a Director at Onconova Therapeutics (NASDAQ: ONTX), Henry Bienen, bought shares of ONTX for $3,800.

This recent transaction increases Henry Bienen’s holding in the company by 78.59% to a total of $9,294. In addition to Henry Bienen, 2 other ONTX executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Onconova Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $564K and GAAP net loss of $5.09 million. In comparison, last year the company earned revenue of $210K and had a GAAP net loss of $8.34 million. Currently, Onconova Therapeutics has an average volume of 2.3M.

Six different firms, including BMO Capital and Leerink Partners, currently also have a Buy rating on the stock.

Henry Bienen’s trades have generated a -64.7% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts